In patients with cervical cancer, the best discrimination was obtained for a cut-off value of post-therapeutic numbers of CD133+ CTCs ≥ 2/ml (83.87% sensitivity and 100% specificity; Supplementary Figure S3D), numbers of CD49f+ CD133+ CTCs ≥ 2/ml (76.67% sensitivity and 100% specificity; Supplementary Figure S3E) and numbers of PD-L1+ CD49f+ CD133+ CTCs ≥ 2/ml (80% sensitivity and 100% specificity; Supplementary Fig. S3F). This evidence concerns the gene ITGA6 and cervical carcinoma.